-

Allurion to Participate in Upcoming Investor Conferences

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be participating in two upcoming investor conferences.

Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at 9:10 a.m. ET and host one-on-one investor meetings throughout the day on March 3, 2025, at the 45th Annual TD Cowen Healthcare Conference in Boston, Massachusetts. Dr. Gaur will also host one-on-one investor meetings at the 37th Annual Roth Conference in Dana Point, California from March 16-18, 2025.

A webcast of the presentation will be available in the Events & Presentations section of Allurion’s investor relations website.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-lessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Contacts

Global Media and Investor Inquiries
Hannah Lindberg
hlindberg@allurion.com

Industry:

Allurion Technologies, Inc.

NYSE:ALUR
Release Versions
English
$Cashtags
$ALUR

Contacts

Global Media and Investor Inquiries
Hannah Lindberg
hlindberg@allurion.com

More News From Allurion Technologies, Inc.

Allurion Reports First Quarter 2025 Financial Results and Provides Business Update

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million...

Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four abstracts at the European Congress on Obesity (ECO) taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtual Care Suite (VCS)—the AI-powered digital platform that includes Coach Iris—on weight loss outcomes and lean body mass...

Allurion to Report First Quarter 2025 Financial Results on May 14, 2025

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will report financial results for the first quarter 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 646 960 0804 (internat...
Back to Newsroom